Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy
| Autor: | Peter Lembessis, Michael Koutsilieris, Antigone Sourla, Theodoros Dimopoulos, Zacharoula Panteleakou, Pavlos Msaouel, Andreas Papaioannou, Constantine Dardoufas, Antonis Halapas, John Bogdanos, Evangelos Maragoudakis, Nikolaos Pissimissis, Constantine Milathianakis |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Glutamate Carboxypeptidase II
Male medicine.medical_specialty Pathology medicine.drug_class Clinical Biochemistry Urology Disease-Free Survival Prostate cancer Antigen Glutamate carboxypeptidase II medicine Humans Prospective Studies RNA Messenger Aged Reverse Transcriptase Polymerase Chain Reaction business.industry Biochemistry (medical) Prostatic Neoplasms Cancer Androgen Antagonists General Medicine Middle Aged Prostate-Specific Antigen medicine.disease Androgen Reverse transcription polymerase chain reaction Prostate-specific antigen Real-time polymerase chain reaction Antigens Surface business |
| Zdroj: | Clinical Chemical Laboratory Medicine. 45 |
| ISSN: | 1437-4331 1434-6621 |
| DOI: | 10.1515/cclm.2007.301 |
| Popis: | The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate cancer is still debatable.We analyzed the biochemical failure-free survival (bFFS) of prostate cancer patients with positive molecular staging who underwent immediate curative therapy (Group I, n=39) compared to prostate cancer patients who did convert their positive molecular staging by the administration of combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II, n=15).The median bFFS for Group I was 9 months (95% CI 5-13 months) and was significantly lower compared to Group II (36 months, p0.001). In Group I, the median time for PSA values of2.0 ng/mL was 18 months (95% CI 12-21 months, range 12-36 months). Notably, only one patient from Group II reached PSA values2.0 ng/mL at 36 months post-curative treatment.In patients with clinically localized prostate cancer and positive RT-PCR detection of PSA and PSMA transcripts in PB, CAB can convert positive molecular staging status to negative and by doing so it modifies the post-curative therapy bFFS of patients with clinically localized prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|